Related Experiment Video
Updated: Nov 1, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
23.7K
First bite syndrome treated with onabotulinumtoxin A injections
Journal of the American Dental Association (1939)
|June 19, 2021
Summary
First bite syndrome (FBS) causes facial pain with eating. Onabotulinumtoxin A injections effectively treated FBS in a post-surgery patient, offering a promising new option for managing this condition.
Area of Science:
- Orofacial pain management
- Neuromodulation therapies
Background:
- First bite syndrome (FBS) is a distinct orofacial pain condition.
- Characterized by unilateral facial pain triggered by the first bite or taste of food.
- Requires awareness of clinical presentation and management strategies for healthcare providers.
Observation:
- A case study of a 43-year-old male patient with FBS is presented.
- The patient developed FBS following a partial parotidectomy for mucoepidermoid carcinoma.
- Orofacial pain was managed with onabotulinumtoxin A injections into residual parotid tissue.
Findings:
- Onabotulinumtoxin A demonstrated significant efficacy in alleviating FBS-associated pain.
- Treatment with onabotulinumtoxin A resulted in minimal adverse effects.
- Successful pain relief was achieved through targeted injections.
Implications:
- Onabotulinumtoxin A represents a promising therapeutic avenue for FBS management.
- Oral healthcare providers should consider onabotulinumtoxin A for patients with FBS.
- This treatment offers profound pain relief with a favorable safety profile.
More Related Videos
12:25Isolation and Quantification of Botulinum Neurotoxin From Complex Matrices Using the BoTest Matrix Assays
Published on: March 3, 2014
16.2K
10:30A High-throughput-compatible FRET-based Platform for Identification and Characterization of Botulinum Neurotoxin Light Chain Modulators
Published on: December 27, 2013
5.5K
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
870
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
870
01:20Myasthenia Gravis: Overview and Treatment
2.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
01:19Depolarizing Blockers: Pharmocokinetics
425
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
425
01:26Anticholinesterase Agents: Poisoning and Treatment
1.2K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.2K
01:31Skeletal Muscle Relaxants: Therapeutic Uses
709
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
709
01:14Prevention of Further Absorption of Poison
1.0K
In cases of acute poisoning, the primary objective is to prevent further absorption of the toxic substance into the body. Immediate interventions using various decontamination techniques targeting the gastrointestinal (GI) tract can achieve this. Decontamination is crucial to prevent poison from entering the systemic circulation, which involves washing affected areas with water and mild soap and removing contaminated clothing. Once external decontamination is done, attention must be turned to...
1.0K